{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:01:45Z","timestamp":1781179305073,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40256-026-00797-6","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:34:31Z","timestamp":1778315671000},"page":"467-484","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Ongericimab in Chinese Patients with Hypercholesterolemia: A Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9381-0106","authenticated-orcid":false,"given":"Muhammad Imaz","family":"Bhatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Safiullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anam Aamir","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"797_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.26599\/1671-5411.2023.06.001","volume":"20","author":"S-S Hu","year":"2023","unstructured":"Hu S-S. Report on cardiovascular health and diseases in China 2021: an updated summary. J Geriatr Cardiol. 2023;20:399\u2013430. https:\/\/doi.org\/10.26599\/1671-5411.2023.06.001.","journal-title":"J Geriatr Cardiol"},{"key":"797_CR2","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"J-J Li","year":"2023","unstructured":"Li J-J, Zhao S-P, Zhao D, Lu G-P, Peng D-Q, Liu J, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934. https:\/\/doi.org\/10.3389\/fphar.2023.1190934.","journal-title":"Front Pharmacol"},{"key":"797_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2021.100286","volume":"17","author":"S Li","year":"2021","unstructured":"Li S, Liu H-H, Guo Y-L, Zhu C-G, Wu N-Q, Xu R-X, et al. Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement: a population-based study. Lancet Reg Health West Pac. 2021;17:100286. https:\/\/doi.org\/10.1016\/j.lanwpc.2021.100286.","journal-title":"Lancet Reg Health West Pac"},{"key":"797_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12944-019-1170-9","volume":"18","author":"T Zhang","year":"2019","unstructured":"Zhang T, Chen J, Tang X, Luo Q, Xu D, Yu B. Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis. Lipids Health Dis. 2019;18:223. https:\/\/doi.org\/10.1186\/s12944-019-1170-9.","journal-title":"Lipids Health Dis"},{"key":"797_CR5","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1604304.","journal-title":"N Engl J Med"},{"key":"797_CR6","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: executive summary: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:3168\u2013209. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.002.","journal-title":"J Am Coll Cardiol"},{"key":"797_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2022.100371","volume":"12","author":"ME Makover","year":"2022","unstructured":"Makover ME, Shapiro MD, Toth PP. There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness. Am J Prev Cardiol. 2022;12:100371. https:\/\/doi.org\/10.1016\/j.ajpc.2022.100371.","journal-title":"Am J Prev Cardiol"},{"key":"797_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","volume":"235","author":"S Zhao","year":"2014","unstructured":"Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014;235:463\u20139. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.05.916.","journal-title":"Atherosclerosis"},{"key":"797_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","volume":"34","author":"R Haynes","year":"2013","unstructured":"HPS2-THRIVE Collaborative Group, Haynes R, Jiang L, Hopewell JC, Li J, Chen F, et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279\u201391. https:\/\/doi.org\/10.1093\/eurheartj\/eht055.","journal-title":"Eur Heart J"},{"issue":"290","key":"797_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","volume":"2019","author":"F Mach","year":"2019","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;2019(290):140\u2013205. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.08.014.","journal-title":"Atherosclerosis"},{"key":"797_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"key":"797_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"key":"797_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033669","volume":"13","author":"X Wang","year":"2024","unstructured":"Wang X, Qiu M, Cheng Z, Ji X, Chen J, Zhu H, et al. Efficacy and safety of ongericimab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia. J Am Heart Assoc. 2024;13:e033669. https:\/\/doi.org\/10.1161\/JAHA.123.033669.","journal-title":"J Am Heart Assoc"},{"key":"797_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119120","volume":"403","author":"J Lin","year":"2025","unstructured":"Lin J, Ji Y, Wang G, Ma X, Yao Z, Han X, et al. Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial. Atherosclerosis. 2025;403:119120. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119120.","journal-title":"Atherosclerosis"},{"key":"797_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2019","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions. 1st ed. Hoboken: Wiley; 2019. https:\/\/doi.org\/10.1002\/9781119536604.","edition":"1"},{"key":"797_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"797_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0976-500X.64539","volume":"1","author":"J Singh","year":"2010","unstructured":"Singh J. Mendeley: a free research management tool for desktop and web. J Pharmacol Pharmacother. 2010;1:62\u20133. https:\/\/doi.org\/10.4103\/0976-500X.64539.","journal-title":"J Pharmacol Pharmacother"},{"key":"797_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"797_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif J-C, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1905239.","journal-title":"N Engl J Med"},{"key":"797_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol. 2024;24:243. https:\/\/doi.org\/10.1186\/s12874-024-02356-6.","journal-title":"BMC Med Res Methodol"},{"key":"797_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16:195\u2013203. https:\/\/doi.org\/10.1097\/XEB.0000000000000141.","journal-title":"Int J Evid Based Healthc"},{"key":"797_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"797_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Sch\u00fcnemann HJ. What is \u201cquality of evidence\u201d and why is it important to clinicians? BMJ. 2008;336:995\u20138. https:\/\/doi.org\/10.1136\/bmj.39490.551019.BE.","journal-title":"BMJ"},{"key":"797_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70061","volume":"17","author":"J Jiang","year":"2024","unstructured":"Jiang J, Xu L, Chai L, Guan X, Zhang L, Liu H, et al. Clinical pharmacokinetics and pharmacodynamics of ongericimab: a potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: randomized, double-blind, placebo-controlled phase Ia and Ib\/II studies. Clin Transl Sci. 2024;17:e70061. https:\/\/doi.org\/10.1111\/cts.70061.","journal-title":"Clin Transl Sci"},{"key":"797_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120408","volume":"407","author":"C Shao","year":"2025","unstructured":"Shao C, Zhang S, Cheng Z, Yang K, Wang G, Shi X, et al. Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial. Atherosclerosis. 2025;407:120408. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120408.","journal-title":"Atherosclerosis"},{"key":"797_CR26","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.numecd.2024.04.011","volume":"34","author":"W Zhao","year":"2024","unstructured":"Zhao W, Cheng Z, Ji X, Pei Z, Yang K, Huang Z, et al. Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia. Nutr Metab Cardiovasc Dis. 2024;34:2217\u201325. https:\/\/doi.org\/10.1016\/j.numecd.2024.04.011.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"797_CR27","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1253\/circj.CJ-20-1051","volume":"85","author":"AC Keech","year":"2021","unstructured":"Keech AC, Oyama K, Sever PS, Tang M, Murphy SA, Hirayama A, et al. Efficacy and safety of long-term evolocumab use among Asiansubjects\u2014a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) Trial. Circ J. 2021;85:2063\u201370. https:\/\/doi.org\/10.1253\/circj.CJ-20-1051.","journal-title":"Circ J"},{"key":"797_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/JCMA.0000000000000062","volume":"82","author":"T-H Chao","year":"2019","unstructured":"Chao T-H, Hsiao P-J, Liu M-E, Wu C-J, Chiang F-T, Chen Z-C, et al. A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab. J Chin Med Assoc. 2019;82:265\u201371. https:\/\/doi.org\/10.1097\/JCMA.0000000000000062.","journal-title":"J Chin Med Assoc"},{"key":"797_CR29","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1253\/circj.CJ-16-0387","volume":"80","author":"T Teramoto","year":"2016","unstructured":"Teramoto T, Kobayashi M, Tasaki H, Yagyu H, Higashikata T, Takagi Y, et al. Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins\u2014ODYSSEY JAPAN randomized controlled trial. Circ J. 2016;80:1980\u20137. https:\/\/doi.org\/10.1253\/circj.CJ-16-0387.","journal-title":"Circ J"},{"key":"797_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11883-004-0104-8","volume":"6","author":"S Fazio","year":"2004","unstructured":"Fazio S, Linton MF. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep. 2004;6:148\u201357. https:\/\/doi.org\/10.1007\/s11883-004-0104-8.","journal-title":"Curr Atheroscler Rep"},{"key":"797_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1524-6175.2005.05278.x","volume":"8","author":"TA Jacobson","year":"2006","unstructured":"Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens. 2006;8:35\u201341. https:\/\/doi.org\/10.1111\/j.1524-6175.2005.05278.x.","journal-title":"J Clin Hypertens"},{"key":"797_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4093\/dmj.2022.0198","volume":"46","author":"K Kim","year":"2022","unstructured":"Kim K, Ginsberg HN, Choi SH. New, novel lipid-lowering agents for reducing cardiovascular risk: beyond statins. Diabetes Metab J. 2022;46:517\u201332. https:\/\/doi.org\/10.4093\/dmj.2022.0198.","journal-title":"Diabetes Metab J"},{"key":"797_CR33","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jacc.2024.02.031","volume":"83","author":"ND Wong","year":"2024","unstructured":"Wong ND, Fan W, Hu X, Ballantyne C, Hoodgeveen RC, Tsai MY, et al. Lipoprotein(a) and long-term cardiovascular risk in a multi-ethnic pooled prospective cohort. J Am Coll Cardiol. 2024;83:1511\u201325. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.031.","journal-title":"J Am Coll Cardiol"},{"key":"797_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.040361","volume":"14","author":"D Patel","year":"2025","unstructured":"Patel D, Koschinsky ML, Agarwala A, Natarajan P, Bhatia HS, Mehta A, et al. Role of lipoprotein(a) in atherosclerotic cardiovascular disease in South Asian individuals. J Am Heart Assoc. 2025;14:eJAHA\/2024\/040361-T. https:\/\/doi.org\/10.1161\/JAHA.124.040361.","journal-title":"J Am Heart Assoc"},{"key":"797_CR35","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2025.14.2.174","volume":"14","author":"JA Kim","year":"2025","unstructured":"Kim JA, Kim NH. Lipoprotein(a) and cardiovascular risk in Asian populations: a comprehensive review. J Lipid Atheroscler. 2025;14:174. https:\/\/doi.org\/10.12997\/jla.2025.14.2.174.","journal-title":"J Lipid Atheroscler"},{"key":"797_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100641","volume":"18","author":"G Kaur","year":"2024","unstructured":"Kaur G, Abdelrahman K, Berman AN, Biery DW, Shiyovich A, Huck D, et al. Lipoprotein(a): emerging insights and therapeutics. Am J Prev Cardiol. 2024;18:100641. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100641.","journal-title":"Am J Prev Cardiol"},{"key":"797_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2025-003490","volume":"12","author":"VQT Ho","year":"2025","unstructured":"Ho VQT, Tran NB, Nguyen N, Arrighini GS, Downes D, Dandamudi M, et al. PCSK9 targeting therapies for familial hypercholesterolaemia: a meta-analysis of efficacy on lipid biomarkers and safety in adults and children across 23 RCTs. Open Heart. 2025;12:e003490. https:\/\/doi.org\/10.1136\/openhrt-2025-003490.","journal-title":"Open Heart"},{"key":"797_CR38","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86404","author":"MU Khalid","year":"2025","unstructured":"Khalid MU, Pervaiz N, Sharif S, Shah SNA. Evaluating the safety and efficacy of moderate-intensity statin combined with ezetimibe in elderly patients with atherosclerotic cardiovascular disease. Cureus. 2025. https:\/\/doi.org\/10.7759\/cureus.86404.","journal-title":"Cureus"},{"key":"797_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02208-w","volume":"20","author":"M Xu","year":"2022","unstructured":"Xu M, Zhu X, Wu J, Zhang Y, Zhao D, Wang X, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b\/2 study. BMC Med. 2022;20:13. https:\/\/doi.org\/10.1186\/s12916-021-02208-w.","journal-title":"BMC Med"},{"key":"797_CR40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","volume":"3","author":"MS Sabatine","year":"2018","unstructured":"Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3:823\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2018.2258.","journal-title":"JAMA Cardiol"},{"key":"797_CR41","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, De Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(09)61965-6.","journal-title":"Lancet"},{"key":"797_CR42","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"key":"797_CR43","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1500858.","journal-title":"N Engl J Med"},{"key":"797_CR44","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.jclinepi.2015.04.013","volume":"68","author":"KA Robinson","year":"2015","unstructured":"Robinson KA, Dinglas VD, Sukrithan V, Yalamanchilli R, Mendez-Tellez PA, Dennison-Himmelfarb C, et al. Updated systematic review identifies substantial number of retention strategies: using more strategies retains more study participants. J Clin Epidemiol. 2015;68:1481\u20137. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.04.013.","journal-title":"J Clin Epidemiol"},{"key":"797_CR45","doi-asserted-by":"publisher","unstructured":"Tan H, Li W, Huang Z, Han Y, Huang X, Li D, et al. Efficacy and safety of evolocumab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia: 12-week primary results of the HUA TUO randomized clinical trial. Cardiol Ther. 2023;12(2):341\u201359. https:\/\/doi.org\/10.1007\/s40119-023-00304-x.","DOI":"10.1007\/s40119-023-00304-x"},{"key":"797_CR46","doi-asserted-by":"publisher","unstructured":"Zhang Y, Pei Z, Chen B, Qu Y, Dong X, Yu B, et al. Ebronucimab in Chinese patients with hypercholesterolemia\u2014a randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab. Pharmacol Res. 2024;207:107340. https:\/\/doi.org\/10.1016\/j.phrs.2024.107340.","DOI":"10.1016\/j.phrs.2024.107340"},{"key":"797_CR47","doi-asserted-by":"publisher","unstructured":"Ray KK, Kallend D, Leiter LA, Raal FJ, Koenig W, Jaros MJ, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J 2022;43:5047\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehac615.","DOI":"10.1093\/eurheartj\/ehac615"},{"key":"797_CR48","doi-asserted-by":"publisher","unstructured":"Chai M, He Y, Zhao W, Han X, Zhao G, Ma X, et al. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med. 2023;21(1):77. https:\/\/doi.org\/10.1186\/s12916-023-02797-8.","DOI":"10.1186\/s12916-023-02797-8"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00797-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-026-00797-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-026-00797-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:38:39Z","timestamp":1781177919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-026-00797-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["797"],"URL":"https:\/\/doi.org\/10.1007\/s40256-026-00797-6","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no financial or personal relationships that could have inappropriately influenced the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data used in this study are publicly available. Further details can be obtained from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Muhammad Imaz Bhatti: Conceptualization, Methodology, Software, Data curation, Writing\u2014Original draft preparation, Supervision, Project Administration; Muhammad Safiullah: Data curation, Writing\u2014Original draft preparation, Visualization, Investigation, Data Curation; Maria Qadri: Data curation, Writing\u2014Original draft preparation, Investigation, Data Curation; Anam Aamir Butt: Visualization, Writing\u2014Reviewing and Editing; Raheel Ahmed: Supervision, Writing\u2014Reviewing and Editing.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Not applicable, as this study involved analysis of publicly available data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable, as this study involves only publicly available data.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}